ES3053508T2 - Liquid pharmaceutical composition of adalimumab - Google Patents
Liquid pharmaceutical composition of adalimumabInfo
- Publication number
- ES3053508T2 ES3053508T2 ES25179059T ES25179059T ES3053508T2 ES 3053508 T2 ES3053508 T2 ES 3053508T2 ES 25179059 T ES25179059 T ES 25179059T ES 25179059 T ES25179059 T ES 25179059T ES 3053508 T2 ES3053508 T2 ES 3053508T2
- Authority
- ES
- Spain
- Prior art keywords
- histidine
- pharmaceutical composition
- liquid pharmaceutical
- composition according
- zwitterionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. REIVINDICACIONES
1. Una composición farmacéutica líquida, que comprende adalimumab; histidina zwitteriónica; y un estabilizador de azúcar; en donde la composición está exenta de aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración colectiva de 0,1 mM como máximo;
en donde la histidina zwitteriónica está presente en una concentración entre 0,77mg/mL y 2,2 mg/mL o en una concentración entre 5 y 14 mM.
2. La composición farmacéutica líquida de acuerdo con la reivindicación 1, que comprende además un tensioactivo.
3. La composición farmacéutica líquida de acuerdo con la reivindicación 1 o la reivindicación 2, que comprende además un tonificante.
4. La composición farmacéutica líquida de acuerdo con cualquier reivindicación anterior, en donde el estabilizador de azúcar es un poliol de azúcar o un disacárido.
5. La composición farmacéutica líquida de acuerdo con la reivindicación 4, en donde el estabilizador de azúcar es trehalosa o manitol.
6. La composición farmacéutica líquida de acuerdo con la reivindicación 2, o cualquier reivindicación anterior dependiente de la misma, en donde el tensioactivo es polisorbato 80 o polisorbato 20.
7. La composición farmacéutica líquida de acuerdo con la reivindicación 3, o cualquier reivindicación anterior dependiente de la misma, en donde el tonificante no es amortiguador.
8. La composición farmacéutica líquida de acuerdo con la reivindicación 3, o cualquier reivindicación anterior dependiente de la misma, en donde el tonificante es o comprende una sal metálica.
9. La composición farmacéutica líquida de acuerdo con la reivindicación 8, en donde el tonificante es o comprende cloruro de sodio.
10. La composición farmacéutica líquida de acuerdo con cualquier reivindicación anterior, en donde la composición farmacéutica líquida comprende:
- Adalimumab;
- 5 a 14 mM de histidina zwitteriónica;
- 100 a 300 mM de un estabilizador de azúcar (por ejemplo, trehalosa);
- 10 a 200 mM un tonificante (por ejemplo, cloruro de sodio); y
Agua para inyección
- en donde la composición:
o tiene un pH entre 6,3 y 6,7 (por ejemplo, pH 6,4)
o está (sustancial o totalmente) libre de arginina; comprende arginina en una concentración de 0,1 mM como máximo;
o está (sustancial o totalmente) libre de aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración (colectiva) de 0,1 mM como máximo;
o está (sustancial o totalmente) libre de tensioactivos con la excepción opcional del polisorbato 80 o comprende uno o más de dichos tensioactivos (excluyendo opcionalmente el polisorbato 80) en una concentración (colectiva) de como máximo 1 mM; y/o
o está (sustancial o totalmente) exenta de agentes amortiguadores de fosfatos (por ejemplo, dihidrogenofosfato de sodio, hidrogenofosfato de disodio) o comprende un sistema de disolución amortiguadora de fosfatos en una concentración de 0,1 mM como máximo.
11. Un método de fabricación de una composición farmacéutica líquida, que comprende adalimumab, histidina zwitteriónica y un estabilizador de azúcar; en donde la composición no contiene aminoácidos distintos de la histidina o comprende uno o más aminoácidos distintos de la histidina en una concentración colectiva de como máximo 0.1 mM; y la composición comprende entre 0,77mg/mL y 2,2 mg/mL de histidina zwitteriónica o entre 5 y 14 mM de histidina zwitteriónica; en donde el método comprende: mezclar juntos, en agua, el adalimumab, la histidina zwitteriónica y el estabilizador de azúcar.
12. El método de acuerdo con la reivindicación 11, en donde el método involucra formar un sistema de disolución amortiguadora de histidina que comprenda la histidina zwitteriónica, en donde formar el sistema de disolución amortiguadora de histidina comprende mezclar la histidina zwitteriónica con clorhidrato de histidina.
13. El método de acuerdo con la reivindicación 11 o la reivindicación 12, en donde la composición farmacéutica líquida es como se reivindica en cualquiera de las reivindicaciones 1 a 10.
14. Una composición farmacéutica líquida de acuerdo con cualquiera de las reivindicaciones 1 a 10, o una
composición farmacéutica líquida obtenida por el método de acuerdo con cualquiera de las reivindicaciones 11 a 13, para su uso en el tratamiento de la artritis reumatoide, la artritis psoriásica, la espondilitis anquilosante, la enfermedad de Crohn, la colitis ulcerosa, la psoriasis crónica de moderada a grave y/o la artritis idiopática juvenil.
15. La composición farmacéutica líquida para su uso de acuerdo con la reivindicación 14, en donde el tratamiento es la artritis psoriásica, la espondilitis anquilosante, la enfermedad de Crohn, la colitis ulcerosa, la psoriasis crónica de moderada a grave y/o la artritis idiopática juvenil.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169754.0A EP2946766B1 (en) | 2014-05-23 | 2014-05-23 | Liquid pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3053508T2 true ES3053508T2 (en) | 2026-01-22 |
Family
ID=50774705
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14169754.0T Active ES2572919T3 (es) | 2014-05-23 | 2014-05-23 | Composición farmacéutica líquida |
| ES15724974.9T Active ES2683194T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES18169979T Active ES2928738T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES19215036T Active ES2955316T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida de adalimumab |
| ES25179059T Pending ES3053508T2 (en) | 2014-05-23 | 2015-05-15 | Liquid pharmaceutical composition of adalimumab |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14169754.0T Active ES2572919T3 (es) | 2014-05-23 | 2014-05-23 | Composición farmacéutica líquida |
| ES15724974.9T Active ES2683194T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES18169979T Active ES2928738T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida |
| ES19215036T Active ES2955316T3 (es) | 2014-05-23 | 2015-05-15 | Composición farmacéutica líquida de adalimumab |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10493152B2 (es) |
| EP (6) | EP2946766B1 (es) |
| JP (3) | JP2017516847A (es) |
| CN (2) | CN108785670A (es) |
| AU (4) | AU2015263246B2 (es) |
| CA (2) | CA3050875A1 (es) |
| CY (1) | CY1120488T1 (es) |
| DE (2) | DE25179059T1 (es) |
| DK (3) | DK3148510T3 (es) |
| ES (5) | ES2572919T3 (es) |
| HK (1) | HK1257026A1 (es) |
| HR (1) | HRP20181226T1 (es) |
| HU (1) | HUE040097T2 (es) |
| IL (1) | IL249117B2 (es) |
| LT (1) | LT3148510T (es) |
| PL (1) | PL3148510T3 (es) |
| PT (1) | PT3148510T (es) |
| RS (1) | RS57772B1 (es) |
| SI (1) | SI3148510T1 (es) |
| SM (1) | SMT201800413T1 (es) |
| WO (1) | WO2015177058A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PL2946765T3 (pl) | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| RU2020131642A (ru) * | 2018-03-29 | 2022-04-29 | Эйрвэй Терапьютикс, Инк. | Способы и композиции, содержащие сурфактантный белок d (sp-d) |
| MX2020010031A (es) | 2018-03-29 | 2021-01-08 | Airway Therapeutics Inc | Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d). |
| WO2020138517A1 (ko) * | 2018-12-24 | 2020-07-02 | 삼성바이오에피스 주식회사 | 항-TNFα 항체를 포함하는 약제학적 조성물 |
| AU2020207124A1 (en) * | 2019-01-11 | 2021-07-29 | Samsung Bioepis Co., Ltd. | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
| CN113727730A (zh) * | 2019-03-18 | 2021-11-30 | 阿尔沃科技Hf公司 | 高浓度TNFα抗体的含水制剂 |
| CN115429751B (zh) * | 2022-09-21 | 2023-11-17 | 景泽生物医药(合肥)股份有限公司 | 一种人重组卵泡刺激素注射剂及其制备方法 |
| WO2025038671A2 (en) * | 2023-08-15 | 2025-02-20 | Amgen Inc. | Acidic buffered intravenous solution stabilizers for use in methods of treatment |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6388197A (ja) * | 1986-09-30 | 1988-04-19 | Tosoh Corp | モノクロナル抗体の安定化方法 |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US5900404A (en) | 1997-08-15 | 1999-05-04 | Amgen Inc. | Chemical modification of proteins to improve biocompatibility and bioactivity |
| US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| CN101048427B (zh) | 2004-07-23 | 2015-01-14 | 健泰科生物技术公司 | 抗体或其片段的结晶 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| EP1891110A2 (en) | 2005-06-07 | 2008-02-27 | Esbatech AG | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| RU2481824C2 (ru) | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| KR20110097772A (ko) | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| SI3409289T1 (sl) * | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| SG184355A1 (en) | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| KR101878369B1 (ko) | 2010-03-22 | 2018-07-16 | 제넨테크, 인크. | 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物 |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| KR20160105535A (ko) * | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| TW201838651A (zh) | 2012-11-01 | 2018-11-01 | 美商艾伯維有限公司 | 穩定雙重可變區域免疫球蛋白蛋白質調配物 |
| CN104707146B (zh) | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| IN2014MU00610A (es) | 2014-02-21 | 2015-09-25 | Tata Motors Ltd | |
| CA2944330A1 (en) | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
| EP2946766B1 (en) * | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PL2946765T3 (pl) | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP3411401A1 (en) * | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| US10980881B2 (en) | 2017-01-11 | 2021-04-20 | Celltrion Inc. | Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine |
| US20230115267A1 (en) | 2020-03-13 | 2023-04-13 | Samsung Bioepis Co., Ltd. | Pharmaceutical liquid composition having increased stability |
-
2014
- 2014-05-23 EP EP14169754.0A patent/EP2946766B1/en not_active Not-in-force
- 2014-05-23 ES ES14169754.0T patent/ES2572919T3/es active Active
-
2015
- 2015-05-15 EP EP15724974.9A patent/EP3148510B1/en not_active Revoked
- 2015-05-15 ES ES15724974.9T patent/ES2683194T3/es active Active
- 2015-05-15 EP EP25179059.8A patent/EP4585614A3/en active Pending
- 2015-05-15 CN CN201810768437.8A patent/CN108785670A/zh active Pending
- 2015-05-15 EP EP19215036.5A patent/EP3659582B1/en active Active
- 2015-05-15 RS RS20180919A patent/RS57772B1/sr unknown
- 2015-05-15 EP EP18169979.4A patent/EP3403646B1/en active Active
- 2015-05-15 US US15/313,480 patent/US10493152B2/en active Active
- 2015-05-15 WO PCT/EP2015/060817 patent/WO2015177058A1/en not_active Ceased
- 2015-05-15 CA CA3050875A patent/CA3050875A1/en not_active Abandoned
- 2015-05-15 JP JP2017513323A patent/JP2017516847A/ja not_active Withdrawn
- 2015-05-15 EP EP23189888.3A patent/EP4249060A3/en active Pending
- 2015-05-15 ES ES18169979T patent/ES2928738T3/es active Active
- 2015-05-15 DK DK15724974.9T patent/DK3148510T3/en active
- 2015-05-15 LT LTEP15724974.9T patent/LT3148510T/lt unknown
- 2015-05-15 SM SM20180413T patent/SMT201800413T1/it unknown
- 2015-05-15 HU HUE15724974A patent/HUE040097T2/hu unknown
- 2015-05-15 ES ES19215036T patent/ES2955316T3/es active Active
- 2015-05-15 DE DE25179059.8T patent/DE25179059T1/de active Pending
- 2015-05-15 PL PL15724974T patent/PL3148510T3/pl unknown
- 2015-05-15 HR HRP20181226TT patent/HRP20181226T1/hr unknown
- 2015-05-15 CA CA2947487A patent/CA2947487C/en active Active
- 2015-05-15 PT PT157249749T patent/PT3148510T/pt unknown
- 2015-05-15 SI SI201530341T patent/SI3148510T1/sl unknown
- 2015-05-15 IL IL249117A patent/IL249117B2/en unknown
- 2015-05-15 ES ES25179059T patent/ES3053508T2/es active Pending
- 2015-05-15 CN CN201580039868.5A patent/CN106659781A/zh active Pending
- 2015-05-15 AU AU2015263246A patent/AU2015263246B2/en not_active Revoked
- 2015-05-15 DE DE23189888.3T patent/DE23189888T1/de active Pending
-
2018
- 2018-08-06 CY CY20181100812T patent/CY1120488T1/el unknown
- 2018-08-27 AU AU2018222887A patent/AU2018222887B2/en active Active
- 2018-09-07 DK DKBA201800071U patent/DK201800071Y4/da not_active IP Right Cessation
- 2018-09-07 DK DKBA201800070U patent/DK201800070Y8/da not_active IP Right Cessation
- 2018-12-17 HK HK18116149.6A patent/HK1257026A1/zh unknown
-
2019
- 2019-10-10 JP JP2019187090A patent/JP6962984B2/ja active Active
- 2019-11-25 US US16/694,627 patent/US10772961B2/en active Active
-
2020
- 2020-02-14 AU AU2020201090A patent/AU2020201090B2/en active Active
- 2020-08-11 US US16/990,954 patent/US11752208B2/en active Active
-
2021
- 2021-10-12 JP JP2021167297A patent/JP2022003091A/ja active Pending
-
2022
- 2022-06-03 AU AU2022203863A patent/AU2022203863A1/en not_active Abandoned
- 2022-11-02 US US17/979,272 patent/US11752209B2/en active Active
- 2022-11-02 US US17/979,309 patent/US12109267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725360A (en) | Liquid pharmaceutical composition | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| ECSP23041058A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| HRP20241660T1 (hr) | Formulacija protutijela anti-cgrp | |
| DE25179059T1 (de) | Flüssige pharmazeutische zusammensetzung von adalimumab | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| PE20130578A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa | |
| HRP20191966T4 (hr) | Stabilizirani neproteinski klostridijalni pripravci toksina | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| HRP20161753T1 (hr) | Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| JP2017516847A5 (es) | ||
| JP2015535237A5 (es) |